Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510973 | 0.83 | KMT2A (0.50) | KMT2AMEN1TSHRCHRNB2CHRNA5 | |
| SCHEMBL29261428 | 0.83 | KMT2A (0.49) | KMT2AMEN1TSHRCHRNB2CHRNA5 | |
| SCHEMBL176857 | 0.82 | F2 (0.45) | KMT2AMEN1TSHRCHRNB2CHRNA5 | |
| SCHEMBL1249246 | 0.81 | HPGD (0.53) | KMT2AMEN1TSHRCHRNB2CHRNA5 | |
| Methyl Benzoate SCHEMBL27774033 | 0.81 | TSHR (0.73) | KMT2AMEN1POLBSCN1ASCN2A | |
| SCHEMBL28495717 | 0.81 | HPGD (0.53) | KMT2AMEN1TSHRCHRNB2CHRNA5 | |
| SCHEMBL17066251 | 0.81 | HRH3 (0.45) | POLBTSHRCHRM1F2LMNA | |
| SCHEMBL29111292 | 0.81 | HPGD (0.58) | POLBTSHRHPGD | |
| SCHEMBL28283562 | 0.81 | F2 (0.44) | KMT2AMEN1POLBSCN1ASCN2A | |
| SCHEMBL27383717 | 0.81 | SIGMAR1 (0.54) | KMT2AMEN1POLBTSHRCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9446046-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| US-20160030430-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| CN-103102314-B | Benzothiazole, benzoglyoxaline, benzoxazole derivative and its production and use | SICHUAN UNIVERSITY (CN) | 2015-09-09 | — | — | CN | disclosed |
| US-9126999-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| CN-104520290-A | Amido spirocyclic amide and sulfonamide derivatives | GENENTECH INC | 2015-04-15 | — | — | CN | disclosed |
| CN-104072498-A | Synthetic method for (R)-N-[5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-yl]-4-(4-methyl piperazine-1-yl)benzamide | UNIV SHENYANG PHARMACEUTICAL | 2014-10-01 | — | — | CN | disclosed |
| CN-104039789-A | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | MERCK PATENT GMBH | 2014-09-10 | — | — | CN | disclosed |
| CN-103102314-A | Benzothiazole, benzimidazole, benzoxazole derivatives and preparation method and application thereof | UNIV SICHUAN | 2013-05-15 | — | — | CN | disclosed |
| CN-103080093-A | Indazole compounds and their uses | DANA FARBER CANCER INST INC | 2013-05-01 | — | — | CN | disclosed |
| CN-102958892-A | Method for preparing chemical compounds of interest by aromatic nucleophilic substitution | CENTRE NAT RECH SCIENT | 2013-03-06 | — | — | CN | disclosed |
| CN-101611014-B | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| CN-101910168-A | Tropane compounds | EXELIXIS INC | 2010-12-08 | — | — | CN | disclosed |
| CN-101805309-A | Benzamide derivatives as histone deacetylase inhibitors | ASTRAZENECA AB | 2010-08-18 | — | — | CN | disclosed |
| CN-101611014-A | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| CN-101511841-A | Tetrahydrofuro [3, 2-B ] pyrrol-3-ones as cathepsin K inhibitors | ARMURA THERAPEUTICS LTD (GB) | 2009-08-19 | — | — | CN | disclosed |
| CN-101506185-A | Tetrahydrofuro [3, 2-B] pyrrol-3-one intermediates | ARMURA THERAPEUTICS LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| CN-1642915-A | Benzamide derivatives useful as inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030430-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | KMT2A 2533/4885MEN1 4767/4885POLB 1445/4885 |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | SSB, TLR8, TLR9 | KMT2A 2533/4885MEN1 4767/4885POLB 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.